

Lipocalin-2 Blocking Peptide
Catalog # PBV10369b**Specification**

Lipocalin-2 Blocking Peptide - Product Information

Primary Accession	P11672
Gene ID	16819
Calculated MW	22875

Lipocalin-2 Blocking Peptide - Additional Information**Gene ID** 16819**Application & Usage**

The peptide is used for blocking the antibody activity of Lipocalin-2. It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30-60 minutes at 37°C.

Other Names

Neutrophil gelatinase-associated lipocalin, NGAL, Lipocalin-2, SV-40-induced 24P3 protein, Siderocalin LCN2, p25, Lcn2

Target/Specificity

Lipocalin-2

Formulation

50 µg (0.5 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 50% glycerol, 1% BSA and 0.02% thimerosal.

Reconstitution & Storage

-20 °C

Background Descriptions**Precautions**

Lipocalin-2 Blocking Peptide is for research use only and not for use in diagnostic or therapeutic procedures.

Lipocalin-2 Blocking Peptide - Protein Information**Name** Lcn2**Function**

Iron-trafficking protein involved in multiple processes such as apoptosis, innate immunity and renal development (PubMed:12453413). Binds iron through association with 2,3-dihydroxybenzoic acid

(2,3- DHBA), a siderophore that shares structural similarities with bacterial enterobactin, and delivers or removes iron from the cell, depending on the context. Iron-bound form (holo-24p3) is internalized following binding to the SLC22A17 (24p3R) receptor, leading to release of iron and subsequent increase of intracellular iron concentration. In contrast, association of the iron-free form (apo-24p3) with the SLC22A17 (24p3R) receptor is followed by association with an intracellular siderophore, iron chelation and iron transfer to the extracellular medium, thereby reducing intracellular iron concentration. Involved in apoptosis due to interleukin-3 (IL3) deprivation: iron-loaded form increases intracellular iron concentration without promoting apoptosis, while iron-free form decreases intracellular iron levels, inducing expression of the proapoptotic protein BCL2L11/BIM, resulting in apoptosis. Involved in innate immunity; limits bacterial proliferation by sequestering iron bound to microbial siderophores, such as enterobactin (PubMed:15531878, PubMed:16446425). Can also bind siderophores from M.tuberculosis (By similarity).

Cellular Location

Secreted. Cytoplasmic granule lumen {ECO:0000250|UniProtKB:P80188}. Cytoplasmic vesicle lumen {ECO:0000250|UniProtKB:P80188}. Note=Upon binding to the SLC22A17 (24p3R) receptor, it is internalized (PubMed:16377569). Releases the bound iron in the acidic lumen of cytoplasmic vesicles (By similarity) {ECO:0000250|UniProtKB:P80188, ECO:0000269|PubMed:16377569}

Tissue Location

Expressed in the cortical tubules of the kidney (at protein level) (PubMed:30418175). Also expressed in the medullary tubules of the kidney (PubMed:30418175). Detected in lung, spleen, uterus, vagina and epididymis (PubMed:8687399)

Lipocalin-2 Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Lipocalin-2 Blocking Peptide - Images